Prognosis of breast cancer in males: an analysis of 170 cases

Salvadori, B; Saccozzi, R; Manzari, Antonia; Andreola, Salvatore; Conti, R; Cusumano, F; Grassi, M.

doi:10.1016/0959-8049(94)90117-1

Cited by 109 publications

(78 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Tumor size and lymph glands involvement represent two obvious prognostic factors for breast cancer in men if it is not disseminated (Salvadori et al, 1994;Schaub et al, 2008). Men with tumor size from two to five cm have for 40% greater risk of death in comparison to men who have a tumor smaller than 2cm (Mustafa et al, 1998), that is five year survival of men with breast cancer smaller than 2cm is 74%, while 37% in those with a tumor greater than 5cm (Guinee et al, 1993).…”

Section: Discussionmentioning

confidence: 99%

Multivariate Analysis of Prognostic Factors in Male Breast Cancer in Serbia

Šipetić-Grujičić

Murtezani²,

Z³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: The aim of this study was to analyze the demographic and clinical characteristics of male breast cancer patients in Serbia, and furthermore to determine overall survival and predictive factors for prognosis. Materials and Methods: In the period of 1996-2006 histopathological diagnosis of breast cancer was made in 84 males at the Institute for Oncology and Radiology of Serbia. For statistical analyses the Kaplan-Meier method, long-rank test and Cox proportional hazards regression model were used. Results: The mean age at diagnosis with breast cancer was 64.3±10.5 years with a range from 35-84 years. Nearly 80% of the tumors showed ductal histology. About 44% had early tumor stages (I and II) whereas 46.4% and 9.5% of the male exhibitied stages III and IV, respectively. Only 7.1% of male patients were grade one. One-fifth of all patients had tumors measuring ≤2 cm, and 14.3% larger than 5 cm. Lymph node metastasis was recorded in 40.4% patients and 47% relapse. Estrogen and progesterone receptor expression was positive in 66.7% and 58.3%, respectively. Among 14.3% of individuals tumor was HER2 positive. About two-thirds of all male patients had radical mastectomy (66.7%). Adjuvant hormonal (tamoxifene), systematic chemotherapy (CMF or FAC) and adjuvant radiotherapy were given to 59.5%, 35.7% and 29.8% patients respectively. Overall survival rates at five and ten years for male breast cancer were 55.0% and 43.9%, respectively. According to the multivariate Cox regression predictive model, a lower initial disease stage, a lower tumor grade, application of adjuvant hormone therapy and no relapse occurrence were significant independent predictors for good overall survival. Conclusions: Results of the treatment would be better if disease is discovered earlier and therefore health education and screening are an imperative in solving this problem.

show abstract

Section: Discussionmentioning

confidence: 99%

Multivariate Analysis of Prognostic Factors in Male Breast Cancer in Serbia

Šipetić-Grujičić

Murtezani²,

Z³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…Male breast carcinoma (MBC) represents only 1% of all mammary cancers (Hecht and Winchester, 1994) and seems to behave more aggressively than female breast carcinomas (FBCs) (Ribeiro, 1985;Salvadori et al, 1994), although no difference in survival between MBC and FBC has been reported (Guinee et al, 1993;Cutuli et al, 1995;Weber-Chappuis et al, 1996). Treatment of MBC is far from standardization because of the uncommon nature of the disease, and no randomized comparisons of treatment have been carried out as in FBC.…”

mentioning

confidence: 99%

Androgen receptor expression in male breast carcinoma: lack of clinicopathological association

et al. 1999

View full text Add to dashboard Cite

Summary Androgen receptor (AR) expression was retrospectively analysed in 47 primary male breast carcinomas (MBCs) using a monoclonal antibody on formalin-fixed, paraffin-embedded tissues. AR immunopositivity was detected in 16 out of 47 (34%) cases. No association was found with patient age, tumour stage, progesterone receptor (PGR) or p53 protein expression. Well-differentiated MBCs tended to be AR positive more often than poorly differentiated ones (P = 0.08). A negative association was found between ARs and cell proliferative activity: MIB-1 scores were higher (25.4%) in AR-negative than in AR-positive cases (21.11%; P = 0.04). A strong positive association (P = 0.0001) was found between ARs and oestrogen receptors (ERs). In univariate analysis, ARs (as well as ERs and PGRs) were not correlated with overall survival; tumour histological grade (P = 0.02), size (P = 0.01), p53 expression (P = 0.0008) and MIB-1 scores (P = 0.0003) had strong prognostic value. In multivariate survival analysis, only p53 expression (P = 0.002) and histological grade (P = 0.02) retained independent prognostic significance. In conclusion, the lack of association between AR and most clinicopathological features and survival, together with the absence of prognostic value for ER/PGR status, suggest that MBCs are biologically different from female breast carcinomas and make it questionable to use antihormonal therapy for patients with MBC.

show abstract

“…Следует отметить, что ввиду отсутствия достаточных для анализа данных оптимальные режимы полихимиотерапии для лечения метастатического рака молочной железы у мужчин пока не определены [1,3,4,6].…”

Section: оригинальные исследованияunclassified

“…Прежде всего это относит-ся к гинекомастии. Далее по частоте возникновения идут воспалительные заболевания молочных желез (субарео-лярный абсцесс, эктазия протоков), не связанные с парен-химой молочной железы, злокачественные новообразо-вания мягких тканей передней стенки грудной клетки (саркомы), а также метастатическое поражение молочной железы [2,3,6].…”

unclassified

Breast Cancer in Men in the Republic of Bashkortostan

Сакаева¹,

Атнабаев²,

Ручкин³

2017

Medicinskij sovet

View full text Add to dashboard Cite

Breast cancer in men is 100 times less common than in women. The principles of treatment of breast cancer in men are still based on knowledge obtained during the treatment of women with a similar pathology. The article reviews 67 cases of all breast cancer stages in men. The majority (50.7%) of all patients who initiated therapy had stage III-IV tumors. In most cases, the patients had an infiltrating ductal carcinoma (52.2%). The combination and complex treatment methods accounted for 53.6% of all cases. The radical mastectomy (89.6%) was the most frequent method of operative intervention. 29 patients (43.3%) received preoperative chemotherapy. 36 patients received adjuvant treatment. The adjuvant treatment comprised chemotherapy (29 patients), and subsequently was supplemented with antihormonal therapy in patients with receptor-positive tumors. The anthracycline-containing chemotherapy was the most prevalent among treatment regimens (72.4%). In 7 patients with a locally diffused process, the treatment was supplemented with radiotherapy. 72.2% of patients had a clinically significant estrogen receptor (RE) expression in the tumor and 61% of patients had a progesterone receptor (RP) expression. 85.0% of patients with stages I-IIA breast cancers showed the relatively high 5-year survival rates, and 67.5% of patients with stage IIB cancers showed 5-year survival. The survival rates for stages III and IV cancer were 18.1% and 16.6%, respectively.

show abstract

Prognosis of breast cancer in males: an analysis of 170 cases

Cited by 109 publications

References 21 publications

Multivariate Analysis of Prognostic Factors in Male Breast Cancer in Serbia

Multivariate Analysis of Prognostic Factors in Male Breast Cancer in Serbia

Androgen receptor expression in male breast carcinoma: lack of clinicopathological association

Breast Cancer in Men in the Republic of Bashkortostan

Contact Info

Product

Resources

About